Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide
Author(s) -
Wolfgang Wick,
Patrick Roth,
Christian Hartmann,
Peter Hau,
Makoto Nakamura,
Florian Stockhammer,
Michael Sabel,
Antje Wick,
Susanne Koeppen,
Ralf Ketter,
Peter Vajkoczy,
Ilker Y. Eyüpoglu,
Rolf Kalff,
Caroline Happold,
Norbert Galldiks,
Friederike SchmidtGraf,
Michael Bamberg,
Guido Reifenberger,
Michael Platten,
Andreas von Deimling,
Christoph Meisner,
Benedikt Wiestler,
Michael Weller
Publication year - 2016
Publication title -
neuro-oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.005
H-Index - 125
eISSN - 1523-5866
pISSN - 1522-8517
DOI - 10.1093/neuonc/now133
Subject(s) - temozolomide , lomustine , procarbazine , medicine , glioma , oncology , progression free survival , anaplastic astrocytoma , dacarbazine , vincristine , chemotherapy , astrocytoma , cancer research , cyclophosphamide
Optimal treatment and precise classification for anaplastic glioma are needed.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom